Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2021-07-31 Call Transcript
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of an analyst/investor conference call for Morepen Laboratories Limited regarding their Q1 FY22 earnings. It includes detailed discussions of quarterly financial results, business segment performance, growth figures, and future plans. The presence of a moderator, management speakers, and Q&A format typical of earnings calls is evident. The document references the quarter ended 30th June 2021 and contains substantive financial data and management commentary. Therefore, this document fits the definition of a Call Transcript (CT).
2021-07-31 English
Please find attached transcript of 'Analyst/ Investor Conference Call' organised on Tuesday, 27th July 2021 at 04.00 P.M. (IST) subsequent to declaration of unaudited standalone and consolidated ....
Call Transcript Classification · 100% confidence The document is a transcript of an analyst/investor conference call for Morepen Laboratories Limited regarding their Q1 FY22 earnings. It includes detailed discussions of financial results, business segment performance, and future plans. The text explicitly mentions it is a transcript of the earnings conference call held on July 27, 2021, following the declaration of unaudited financial results for the quarter ended June 30, 2021. The content includes management commentary, financial figures, and Q&A format typical of earnings call transcripts. Therefore, the document fits the category of a Call Transcript (CT).
2021-07-31 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the loss of a share certificate, referencing Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements). It is an official notification about a share certificate issue, not a financial report, earnings release, or management information. The content is regulatory in nature and does not fit into categories like Annual Report, Earnings Release, or Capital Update. It is a regulatory announcement related to shareholding documentation. Given the nature and length, it fits best under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2021-07-31 English
Pursuant to the Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find attached herewith letter dated 30th July, 2021, ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) regarding the loss of a share certificate and the request for issuance of duplicate share certificates. It references Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to share certificate loss and related disclosures. The content is an official notification about a shareholder's lost share certificate and does not contain financial data, management discussion, or report publication. It is not an annual report, earnings release, or any financial report. It is also not a director's dealing or shareholding notification but rather a regulatory disclosure about share certificate loss. This type of document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-07-31 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the issue of duplicate share certificates. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulation 39(3). The content is about informing the exchange about a corporate action related to share certificates, not a financial report, earnings release, or management discussion. The document length is short (1515 characters) and it is an announcement of a corporate action rather than a report or detailed filing. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-07-28 English
Pursuant to the Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find attached herewith letter dated 27th July, 2021, ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) regarding the issuance of duplicate share certificates. It references Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to share certificate management. The content is about administrative action related to share certificates, specifically the issuance of duplicates, and includes details of old and new certificate numbers and shareholder names. There is no financial data, no discussion of financial results, no management commentary, no voting results, no legal proceedings, no capital changes, and no report publication. This is a regulatory announcement related to share certificates and does not fit into categories like Annual Report, Earnings Release, or Capital Update. It is not a report but an official notification to the stock exchanges. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. The document length is 4033 characters, which is relatively short and consistent with a regulatory filing rather than a full report.
2021-07-28 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.